EPH1 Screening for Clinically Relevant Drug-Drug Interactions between Direct Oral Anticoagulants and Antineoplastic Agents: A Pharmacovigilance Approach

Abstract

Use of direct oral anticoagulants (DOACs) in patients with cancer remains suboptimal due partly to concerns with their potential drug-drug interactions (DDIs) with antineoplastic treatments. However, the clinical relevance of these DDIs is unknown.